Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5617322 | 0.89 | DRD2 (0.57) | DRD2DRD4DRD3KCNH2SIGMAR1 | |
| SCHEMBL5617297 | 0.86 | DRD3 (0.62) | DRD2DRD3SIGMAR1HTR1AHTR2A | |
| SCHEMBL5617240 | 0.85 | DRD3 (0.56) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL5656309 | 0.81 | KCNH2 (0.67) | DRD2DRD4DRD3KCNH2SIGMAR1 | |
| SCHEMBL5617278 | 0.80 | HSD17B10 (0.49) | DRD2SIGMAR1HTR1AHTR2AHTR7 | |
| SCHEMBL5617441 | 0.80 | DRD3 (0.57) | DRD2DRD4DRD3HTR1AHTR2A | |
| SCHEMBL9483832 | 0.78 | KCNH2 (0.74) | DRD2DRD4KCNH2SIGMAR1HTR1A | |
| SCHEMBL5617429 | 0.77 | DRD2 (0.59) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL5657775 | 0.77 | DRD2 (0.62) | DRD2DRD4DRD3KCNH2SIGMAR1 | |
| SCHEMBL30767216 | 0.76 | KCNH2 (0.90) | DRD2KCNH2SIGMAR1HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060704-B2 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON MANUFACTURING, LTD. (US) | 2006-06-13 | — | — | US | claimed |
| US-20050187214-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON RESEARCH, LTD. | 2005-08-25 | — | — | US | claimed |
| EP-1079763-A2 | SEROTONERGIC 5HT 7? RECEPTOR COMPOUNDS FOR TREATING OCULAR AND CNS DISORDERS | ALCON LABORATORIES, INC. (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999059499-A2 | SEROTONERGIC 5HT7 RECEPTOR COMPOUNDS FOR TREATING OCULAR AND CNS DISORDERS | ALCON LABORATORIES, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| US-7285553-B2 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON MANUFACTURING, LTD. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7060704-B2 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON MANUFACTURING, LTD. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20060052372-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON RESEARCH, LTD. | 2006-03-09 | — | — | US | disclosed |
| US-6960579-B1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON MANUFACTURING, LTD. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050187214-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | ALCON RESEARCH, LTD. | 2005-08-25 | — | — | US | disclosed |
| EP-1079763-A2 | SEROTONERGIC 5HT 7? RECEPTOR COMPOUNDS FOR TREATING OCULAR AND CNS DISORDERS | ALCON LABORATORIES, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999059499-A2 | SEROTONERGIC 5HT7 RECEPTOR COMPOUNDS FOR TREATING OCULAR AND CNS DISORDERS | ALCON LABORATORIES, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052372-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | HTR7, HTR1A, HTR2B | DRD2 31/4885DRD4 30/4885DRD3 52/4885 |
| US-20050187214-A1 | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders | HTR7, HTR1A, HTR2B | DRD2 31/4885DRD4 30/4885DRD3 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.